This is the standing evidence sheet for Abbvie (ABBV): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Today the market pays about $113.9 for each $1 of Abbvie’s annual profit (a price-to-earnings ratio of 113.9). Across its own past decade the typical price tag was 51.0, which puts today at roughly the 100th percentile of the company’s own history.
The tape: what the stock itself has done
- Last price: $281.12 (end-of-day market data as of the edition date · methodology) · 0% below its 52-week high
- Past 6 months: +36.2% · past 12 months: +21.9%
- Day-to-day temperament: jumpy (annualized volatility 25%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $56.2B | +22.7% | 31.9% | $6.45 |
| FY2022 | $58.1B | +3.3% | 31.2% | $6.63 |
| FY2023 | $54.3B | -6.4% | 23.5% | $2.72 |
| FY2024 | $56.3B | +3.7% | 16.2% | $2.39 |
| FY2025 | $61.2B | +8.6% | 24.6% | $2.36 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|---|---|
| Net sales ($B) | 54.3 | 56.3 | 61.2 | 66.5 to 68.5 | 70.0 to 75.0 | 72.2 to 81.0 |
| Net sales growth (%) | +3.7 | +3.7 | +8.7 | 9 to 12 | 5 to 9 | 4 to 6 |
| Operating margin (%) | 23.6 | 16.2 | 24.6 | 22.5 to 25.5 | 23.0 to 26.5 | 22.0 to 27.0 |
| Diluted EPS ($) | 0.46 | -0.02 | 1.02 | 0.54-1.84 | 0.22-2.22 | -1.01-3.49 |
| Adjusted EPS (non-GAAP) | 11.11 | 10.12 | 12.12 | 14.00 to 15.20 | 15.00 to 17.00 | 15.50 to 18.75 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Abbvie
- AbbVie’s October Surprise: A $216 Million Charge and a Pipeline That Keeps Growing Anyway
- AbbVie at $257: The Price That Needs Everything to Go Right
- AbbVie Reaffirms 2026 Guidance After Closing $10.9 Billion Apogee Acquisition
- AbbVie: Two Drugs Are Doing the Work of an Entire Company
Read the full report on Abbvie in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-10-06. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
